Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation

Inclusion Criteria: * Inpatient but hospitalized \< 14 days prior to enrollment * Requires PN because oral or enteral nutrition is not possible, insufficient, or contraindicated * Has capability to complete at least 5 days of study treatment (i.e., PN) * Has a useable peripheral vein for delivery of intravenous (IV) PN Exclusion Criteria: * Has a life expectancy of \< 6 days from initiation of study treatment, in the opinion of the Investigator * Known hypersensitivity to the components of either of the investigational study treatments * Use of prohibited medications (e.g. glucocorticosteroids or antitumor chemotherapeutic agents) within 30 days prior to enrollment * Known serious clinically significant condition that would preclude participation in the study * Known chronic active hepatitis, elevated liver function tests * Known history of human immunodeficiency virus infection * Known severe dyslipidemia, severe hyperglycemia,clinically significant abnormalities of plasma electrolytes * Known pregnancy or lactation